A Phase 3 interventional study of AG-348 in Pyruvate Kinase Deficiency and Anemia, Hemolytic, sponsored by Agios Pharmaceuticals, Inc.. Completed at 19 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-04.
Sponsored by Agios Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Anemia, Hemolytic with a site in United States — 8 open to participants now, 11 under way, 1 of them phase 3. Anemia, Hemolytic · United States.
Among the 35 studies in Anemia, Hemolytic with a site in United States, this one is the 17th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2018, is one of 4 in phase 3, and was the 16th registered.
56 studies on the registry are indexed under Anemia, Hemolytic; 16 are open to participants now.
Browse Anemia, Hemolytic studies →8 of the 35 studies in Anemia, Hemolytic with a site in United States are open now. Recruiting first, the newest first:
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–90
International PNH Interest Group · Sites in United States
Apellis Pharmaceuticals, Inc. · Sites in United States, Czechia, France and 6 more countries
Ages 12–17
Children's Hospital Medical Center, Cincinnati · Sites in United States
Insel Gruppe AG, University Hospital Bern · Sites in United States, Austria, Czechia and 4 more countries
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Anemia, Hemolytic studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 6 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 4 · Phase 4 3
First in 1997; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 48 across 39 interventional studies indexed under Anemia, Hemolytic.
Median enrollment 47 across the 26 interventional studies, 254 across the 9 observational. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 35 have an industry lead sponsor. The 10 most frequent:
Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.
Agios Pharmaceuticals, Inc. has 5 studies filed under Anemia, Hemolytic — fewer than ten, so there is no comparison to draw.
2 of the studies in Anemia, Hemolytic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07566494National Heart, Lung, and Blood Institute (NHLBI)Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease | 2027-04-27 |
| NCT07612345University of UtahHigh-Dose Vitamin C in G6PDA and Pyruvate Kinase Deficiency: A Safety Study | 2027-07-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 35 studies in Anemia, Hemolytic with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study AG348-C-007 was a multicenter study designed to evaluate the efficacy and safety of treatment with AG-348 in a minimum of 20, with up to 40, participants with pyruvate kinase (PK) deficiency, who were regularly receiving blood transfusions. The study was composed of two parts. During Part 1, Dose Optimization Period, participants started on a dose of 5 mg AG-348 administered twice daily. Over the course of Part 1 each participant's dose of AG-348 was sequentially increased to 20 mg twice a day, followed by 50 mg twice a day depending on their tolerance. During Part 2, Fixed-Dose Period, participants received AG-348 at their optimized dose from Part 1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received AG-348 tablets, administered orally, at a starting dose of 5 milligrams (mg), twice daily (BID), followed by two sequential dose level increases to 20 mg and 50 mg BID, for a period of 16 weeks in Part 1. This was followed by optimized dose BID, as determined by the investigator in Part 1, for a period of 24 weeks in Part 2.
Drug: AG-348
Part 1 (Dose Optimization Period): Participants began by receiving 5 mg orally, BID. Each participant's dose of AG-348 was sequentially increased to 20 mg BID followed by 50 mg BID depending on their response to AG-348 and their tolerance. Part 2 (Fixed Dose Period): Optimized dose determined in Part 1.
Percentage of Participants Achieving a Reduction in Transfusion Burden in Part 2
Reduction in transfusion burden is defined as a ≥33% reduction in the number of RBC units transfused during the Fixed Dose Period standardized to 24 weeks compared with the historical transfusion burden standardized to 24 weeks (Standardized Control Period). The on-study (Fixed Dose Period) transfusion burden was calculated as the total number of transfused RBC units received in the Fixed Dose Period standardized to 24 weeks.
Time frame: From Part 2, Day 1 to Part 2 Week 24
Annualized Number of RBC Units Transfused During the Study
The annualized total number of RBC units transfused during the entire study (both Part 1 and Part 2) is reported. It was calculated as the total number of RBC units transfused up to the end of Fixed Dose Period divided by the total number of days from the first dose date until the end date of Fixed Dose Period × 52.
Time frame: Part 1 Day 1 to Part 2 Week 24
Number of Transfusion Episodes in Part 2
This is the number of transfusion episodes in Part 2. The number of transfusion episodes were standardized to 24 weeks. Transfusions received over up to 3 consecutive days were counted as 1 episode.
Time frame: From Part 2 Day 1 to Part 2 Week 24
Percentage of Transfusion-Free Participants in Part 2
Transfusion-free responders were the participants who were transfusion-free in Part 2.
Time frame: From Part 2 Day 1 to Part 2 Week 24
Percentage of Participants Achieving Normal Hemoglobin (Hb) Concentrations in Part 2
This is the percentage of participants who achieved hemoglobin (Hb) concentrations in the normal range at least once, 8 weeks or more after a transfusion in Part 2.
Time frame: From Part 2 Day 1 to Part 2 Week 24
Percentage of Participants With Adverse Events
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study drug. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Through 4 weeks after last dose (approximately Part 2, Week 31)
Percentage of Participants Experiencing an Adverse Event of Special Interest (AESI)
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AESI can be serious or non-serious.
Time frame: From Part 1 Day 1 to end of Part 2, including follow-up (Day 197)
Bone Mineral Density Z-Score
Time frame: Part 1, Day 1, Part 2, Day 1 and Part 2, Week 24
Bone Mineral Density T-Score
Time frame: Part 1, Day 1, Part 2, Day 1 and Part 2, Week 24
A total of 27 participants were enrolled and treated in the study which was conducted across multiple sites in 9 countries: United States, Canada, Denmark, France, Ireland, Italy, Netherlands, Thailand, and United Kingdom. The study was conducted from 26 June 2018 to 12 November 2020.
| Milestone | AG-348 |
|---|---|
| Started | 27 |
| Completed | 20 |
| Not completed | 7 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Lost to follow-up | 1 |
Reduction in transfusion burden is defined as a ≥33% reduction in the number of RBC units transfused during the Fixed Dose Period standardized to 24 weeks compared with the historical transfusion burden standardized to 24 weeks (Standardized Control Period). The on-study (Fixed Dose Period) transfusion burden was calculated as the total number of transfused RBC units received in the Fixed Dose Period standardized to 24 weeks.
| percentage of participants | AG-348 |
|---|---|
| Percentage of Participants Achieving a Reduction in Transfusion Burden in Part 2 | 37 (19.4 to 57.6) |
The annualized total number of RBC units transfused during the entire study (both Part 1 and Part 2) is reported. It was calculated as the total number of RBC units transfused up to the end of Fixed Dose Period divided by the total number of days from the first dose date until the end date of Fixed Dose Period × 52.
| RBC units | AG-348 |
|---|---|
| Annualized Number of RBC Units Transfused During the Study | 11.52 ± 10.543 |
This is the number of transfusion episodes in Part 2. The number of transfusion episodes were standardized to 24 weeks. Transfusions received over up to 3 consecutive days were counted as 1 episode.
| transfusion episodes | AG-348 |
|---|---|
| Number of Transfusion Episodes in Part 2 | 2.88 ± 2.694 |
Transfusion-free responders were the participants who were transfusion-free in Part 2.
| percentage of participants | AG-348 |
|---|---|
| Percentage of Transfusion-Free Participants in Part 2 | 22.2 (8.6 to 42.3) |
This is the percentage of participants who achieved hemoglobin (Hb) concentrations in the normal range at least once, 8 weeks or more after a transfusion in Part 2.
| percentage of participants | AG-348 |
|---|---|
| Percentage of Participants Achieving Normal Hemoglobin (Hb) Concentrations in Part 2 | 11.1 (2.4 to 29.2) |
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study drug. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| percentage of participants | AG-348 |
|---|---|
| Percentage of Participants With Adverse Events | 100 |
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AESI can be serious or non-serious.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over From Part 1 Day 1 to end of Part 2, including follow-up (up to Day 197). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AG-348 | 0/27 (0%) | 3/27 (11.1%) | 27/27 (100%) |
| Event | AG-348 |
|---|---|
| Blood Triglyceride IncreasedInvestigations | 1/27 |
| Ovarian CystReproductive system and breast disorders | 1/27 |
| Renal ColicRenal and urinary disorders | 1/27 |
| Event | AG-348 |
|---|---|
| HeadacheNervous system disorders | 10/27 |
| Alanine aminotransferase increasedInvestigations | 10/27 |
| NauseaGastrointestinal disorders | 5/27 |
| Aspartate aminotransferase increasedInvestigations | 5/27 |
| FatigueGeneral disorders | 5/27 |
| NasopharyngitisInfections and infestations | 4/27 |
| Upper respiratory tract infectionInfections and infestations | 4/27 |
| Viral upper respiratory tract infectionInfections and infestations | 4/27 |
| VomitingGastrointestinal disorders | 4/27 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/27 |
Full analysis set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | AG-348 |
|---|---|
| Mean | 36.6 ± 13.89 |
| Sex: Female, Male(Participants) | AG-348 |
|---|---|
| Female | 20 |
| Male | 7 |
| Ethnicity (NIH/OMB)(Participants) | AG-348 |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 20 |
| Unknown or Not Reported | 7 |
| Race (NIH/OMB)(Participants) | AG-348 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 20 |
| More than one race | 0 |
| Unknown or Not Reported | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2018 to primary completion in Nov 2020, 28 months.
Results were first posted in Dec 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mitapivat